Jeff Evanson - 21 Dec 2021 Form 4 Insider Report for Outlook Therapeutics, Inc. (OTLK)

Role
Chief Commercial Officer
Signature
/s/ Lawrence Kenyon, Attorney-in-Fact
Issuer symbol
OTLK
Transactions as of
21 Dec 2021
Net transactions value
$0
Form type
4
Filing time
23 Dec 2021, 16:32:10 UTC
Previous filing
06 Dec 2021
Next filing
04 Apr 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OTLK Stock Option (Right to Buy) Award $0 +800,000 $0.000000 800,000 21 Dec 2021 Common Stock 800,000 $1.44 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option shall vest on December 21, 2022, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date. The option is also subject to acceleration under certain circumstances.